» Articles » PMID: 38001654

BRAF Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001654
Authors
Affiliations
Soon will be listed here.
Abstract

BRAF positivity is associated with increased aggressiveness of papillary thyroid cancer (PTC), and age is an important prognostic factor. However, the association between age and BRAF positivity and the recurrence risk has not been investigated. This study aimed to investigate the impact of age on recurrence between patients with BRAF-positive and -negative PTC. Patients with PTC who underwent initial thyroid surgery between January 2010 and December 2018 at Seoul St. Mary's Hospital (Seoul, Republic of Korea) were retrospectively reviewed. The BRAF-positive ( = 1768) and BRAF-negative groups ( = 428) were divided into two subgroups: younger (<35 years) and older groups (≥55 years). In the BRAF-positive group, the younger group exhibited higher lymphatic and vascular invasion rates, more positive lymph nodes, higher lymph node ratios, and higher recurrence rates than the older group (5.9% vs. 2.1%). Multivariate analysis revealed that age, lymphatic invasion, and N category were significant risk factors in the BRAF-positive group. In the BRAF-positive group, the younger group had a higher recurrence risk than the older group (OR, 2.528; 95% confidence interval, 1.443-4.430; = 0.001). In the BRAF-negative group, age had no impact on recurrence risk. These results contribute to tailored treatment strategies and informed patient management.

Citing Articles

Association between breast cancer risk factors and blood microbiome in patients with breast cancer.

An J, Kwon H, Oh S, Kim Y Sci Rep. 2025; 15(1):6115.

PMID: 39972005 PMC: 11840066. DOI: 10.1038/s41598-025-90180-3.

References
1.
Lin K, Wang O, Zhang X, Dai X, Hu X, Qu J . The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol. 2010; 17(12):3294-300. DOI: 10.1245/s10434-010-1129-6. View

2.
Nam J, Jung C, Song B, Lim D, Chae B, Lee N . Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?. Am J Surg. 2011; 203(4):436-41. DOI: 10.1016/j.amjsurg.2011.02.013. View

3.
Soares P, Trovisco V, Rocha A, Lima J, Castro P, Preto A . BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003; 22(29):4578-80. DOI: 10.1038/sj.onc.1206706. View

4.
Nylen C, Mechera R, Marechal-Ross I, Tsang V, Chou A, Gill A . Molecular Markers Guiding Thyroid Cancer Management. Cancers (Basel). 2020; 12(8). PMC: 7466065. DOI: 10.3390/cancers12082164. View

5.
Wang J, Liu J, Pan H, Jiang C, Liu S, Zhu Z . Young age increases the risk of lymph node positivity in papillary thyroid cancer patients: a SEER data-based study. Cancer Manag Res. 2018; 10:3867-3873. PMC: 6163014. DOI: 10.2147/CMAR.S167774. View